FORBEARANCE AGREEMENT AND MODIFICATION NO. 4 TO LOAN AND SECURITY AGREEMENTForbearance Agreement and Modification to Loan and Security Agreement • January 16th, 2019 • Cancer Genetics, Inc • Services-medical laboratories
This FORBEARANCE AGREEMENT AND MODIFICATION NO. 4 TO LOAN AND SECURITY AGREEMENT (this “Agreement”) is made and entered into as of January 16, 2019, by and among PARTNERS FOR GROWTH IV, L.P., a Delaware limited partnership (“PFG”), as lender, and each of (i) CANCER GENETICS, INC., a Delaware corporation (“Parent”), (ii) GENTRIS, LLC, a Delaware limited liability company (“Delaware Subsidiary”), (iii) VIVOPHARM, LLC, a Delaware limited liability company (“Vivo”), and (iv) RDDT A VIVOPHARM COMPANY PTY LTD, a company incorporated under the laws of Australia (“Australian Borrower”, and together with Parent, Delaware Subsidiary and Vivo, jointly and severally, individually and separately, “Borrower”).
FORBEARANCE AND FIFTH AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY agreementLoan and Security Agreement • January 16th, 2019 • Cancer Genetics, Inc • Services-medical laboratories
This Forbearance and Fifth Amendment to Amended and Restated Loan and Security Agreement (this “Amendment”) is entered into this 16th day of January, 2019 by and among (a) SILICON VALLEY BANK, a California corporation (“Bank”), and (b) (i) CANCER GENETICS, INC., a Delaware corporation (“Parent”), (ii) GENTRIS, LLC, a Delaware limited liability company (“Delaware Subsidiary”), (iii) VIVOPHARM, LLC, a Delaware limited liability company (“Vivo”), and (iv) RDDT A VIVOPHARM COMPANY PTY LTD, a company incorporated under the laws of Australia (“Australian Borrower”, and together with Parent, Delaware Subsidiary, and Vivo, jointly and severally, individually and collectively, “Borrower”).
